Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 15.6 kDa. The protein migrates as 35-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD47 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Immobilized Human SIRP alpha, Fc Tag (Cat. No. SIA-H5251) at 5 μg/mL (100 μL/well) can bind Human CD47 Protein, His Tag (Cat. No. CD7-H522a) with a linear range of 7.8-62.5 ng/mL (QC tested).
Immobilized Anti-CD47 MAb, Human IgG4 (clone 5F9) at 2 μg/mL (100 μL/well) can bind Human CD47 Protein, His Tag (Cat. No. CD7-H522a) with a linear range of 0.05-3 ng/mL (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
SG404 | SG-404; SG404 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Neoplasms | Details |
Anti-CD47 monoclonal antibody (Biocad) | Phase 1 Clinical | Biocad | Neoplasms | Details | |
IMM2505 | IMM2505 | Phase 1 Clinical | Shenghe (China) Biopharmaceutical Co Ltd | Solid tumours | Details |
JMT-601 | JMT-601 | Phase 1 Clinical | Shanghai Jinmante Biological Technology Co Ltd | Lymphoma, Non-Hodgkin | Details |
SG12473 | SG12473; SG-12473 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
Recombinant humanized anti-CD-47 monoclonal antibody (Shandong New Time Pharmaceutical) | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma | Details | |
Kintuzumab(GenSci) | Phase 1 Clinical | Changchun Genescience Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Lymphoma | Details | |
CPO-107 | Conjupro Biotherapeutics Inc | Details | |||
HX-009 | HX-009 | Phase 2 Clinical | Hanx Biopharmaceutical Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lymphoma | Details |
CC-90002 | INBRX-103; CC-90002 | Phase 1 Clinical | Inhibrx | Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
BAT-7104 | BAT-7104 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
SG-2501 | SG-2501 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
TQB-2928 | TQB-2928 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
IMM-2902 | IMM-2902 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
NI-1801 | NI-1801 | Phase 1 Clinical | Light Chain Bioscience Ltd | Solid tumours; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
TG-1801 | NI-1701; TG-1801 | Phase 1 Clinical | Novimmune Sa | Lymphoma, B-Cell | Details |
PF-07257876 | Phase 1 Clinical | Pfizer Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details | |
Monoclonal Antibody (Mab) sB24M | Phase 1 Clinical | Swiss Biopharma Med GmbH | Pyoderma Gangrenosum; Pyoderma | Details | |
AL-008 | AL-008; IBI-397 | Phase 1 Clinical | Alector | Neoplasms | Details |
SL-172154 | SL-172154 | Phase 1 Clinical | Shattuck Labs Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Myelodysplastic Syndromes; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms | Details |
SHS-009 | SHS-009; SH009; SH-009 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Neoplasms | Details |
Ligufalimab | AK-117 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Myelodysplastic Syndromes; Breast Neoplasms; Lymphoma; Leukemia, Myeloid, Acute | Details |
ZL-1201 | ZL-1201 | Phase 1 Clinical | Zai Lab (Shanghai) Co Ltd | Solid tumours; Hematologic Neoplasms; Neoplasms | Details |
Simridarlimab | IBI-322; IBI322 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Bone Marrow Neoplasms; Hematologic Neoplasms; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma | Details |
Recombinant humanized monoclonal antibody MIL95(Mabworks/Connaught Biomedical Technology) | MIL-95; CM-312 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd, Keymed Biosciences Co Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma | Details |
IMC-002(Immuneoncia) | IMC-002; 3D-197; 3D197 | Phase 1 Clinical | Immuneoncia Therapeutics Inc | Solid tumours; Hematologic Neoplasms; Neoplasms; Lymphoma; Neoplasm Metastasis | Details |
STI-6643 | STI-6643 | Phase 1 Clinical | Sorrento Therapeutics Inc | Solid tumours; Neoplasms | Details |
Evorpacept | ALX148; ALX-148 | Phase 3 Clinical | Alexo Therapeutics | Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Myelodysplastic Syndromes; Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Adenocarcinoma; Neoplasm Metastasis | Details |
Letaplimab | IBI-188 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Myeloproliferative Disorders; Neoplasms; Adenocarcinoma of Lung; Myelodysplastic Syndromes; Osteosarcoma; Leukemia, Myeloid, Acute | Details |
ISB-1442 | ISB 1442; ISB-1442 | Phase 2 Clinical | Ichnos Sciences Sa | Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
PT-217 | PT-217 | Phase 1 Clinical | Phanes Therapeutics Inc | Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
6MW-3211 | 6MW3211; 6MW-3211 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma, Renal Cell; Neoplasms; Myelodysplastic Syndromes; Lung Neoplasms; Lymphoma; Leukemia, Myeloid, Acute | Details |
Lemzoparlimab | TJC-4; ABBV-IMAB-TJC4; TJ-1133; TJ-011133 | Phase 3 Clinical | I-Mab Biopharma Co Ltd, Abbvie Inc | Hematologic Neoplasms; Solid tumours; Myelodysplastic Syndromes; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma | Details |
SG-1906 | SG-1906; SG1906 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Neoplasms | Details |
Ontorpacept | TTI-621 | Phase 2 Clinical | The Hospital For Sick Children, University Health Network, Trillium Therapeutics Inc | Lymphoma, Follicular; Mycosis Fungoides; Melanoma; Carcinoma, Squamous Cell; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Sarcoma; Breast Neoplasms; Primary mediastinal B cell lymphoma; Lymphoma, B-Cell; Multiple Myeloma; Papillomavirus Infections; Skin Neoplasms; Lymphoma, Large B-Cell, Diffuse; Composite Lymphoma; Solid tumours; Hematologic Neoplasms; Leiomyosarcoma | Details |
IMM-2520 | IMM-2520 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours | Details |
BC-007 (Dragonboat Biopharmaceutical) | BC-007 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Neoplasms | Details |
AUR-103 | AUR-103 | Phase 1 Clinical | Aurigene | Leukemia; Solid tumours; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute | Details |
AUR-105 | AUR-105 | Phase 1 Clinical | Aurigene | Solid tumours; Hodgkin Disease; Lymphoma, Non-Hodgkin | Details |
IMM 01(ImmuneOnco Biopharma) | IMM01; IMM 01 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Hodgkin Disease; Multiple Myeloma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma | Details |
IMM-0306 | IMM-0306 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Lymphoma, B-Cell | Details |
HMPL-A83 | HMPL-A-83; HMPL-A83 | Phase 1 Clinical | Solid tumours; Hematologic Neoplasms; Neoplasms | Details | |
AO-176 | AO-176; Ti-104; Ti-108; Ti-176 | Phase 2 Clinical | Arch Oncology Inc | Solid tumours; Multiple Myeloma | Details |
TTI-622 | TTI-622; PF-07901801 | Phase 2 Clinical | Trillium Therapeutics Inc | Ovarian Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Composite Lymphoma; Multiple Myeloma; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Peritoneal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details |
PT-886 | PT-886 | Phase 1 Clinical | Phanes Therapeutics Inc | Stomach Neoplasms; Pancreatic Neoplasms | Details |
DSP-107 | DSP-107; KAHR-107 | Phase 2 Clinical | Kahr Medical | Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
Magrolimab | 5-F-9; Hu5F9-G4; ONO-7913 | Phase 3 Clinical | Stanford University | Multiple Myeloma; Mycosis Fungoides; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Sezary Syndrome; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Brain Neoplasms; Neuroblastoma; Osteosarcoma; Lymphoma, B-Cell; Myelodysplastic Syndromes; Triple Negative Breast Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Leukemia, Lymphoid; Ovarian Neoplasms; Leukemia, Myeloid; Hematologic Neoplasms; Solid tumours; Lymphoma, B-Cell, Marginal Zone | Details |
RRx-001 | ABDNAZ; RRx-001 | Phase 3 Clinical | Epicentre Biotechnologies Llc | Cholangiocarcinoma; Stomatitis; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Brain metastases; Carcinoma, Small Cell; Lymphoma; Colorectal Neoplasms; Brain Neoplasms; Solid tumours; Central Nervous System Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Neoplasms; Carcinoma, Ovarian Epithelial; Glioblastoma; Small Cell Lung Carcinoma | Details |
This web search service is supported by Google Inc.